

## PUBLICATIONS

### *Original Research Manuscripts:*

1. David S, Lancaster T, Stead LF. Opioid antagonists for smoking cessation. *Cochrane Database Syst Rev*. 2001;(3):CD003086.
2. David S, DeJong W, Resnick N. International tobacco control: a focus group study of U.S. anti-tobacco activists. *J Public Health Policy*. 2001;22(4):415-28.
3. David SP, Johnstone E, Griffiths SE, Murphy M, Yudkin P, Mant D, Walton R. No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. *Pharmacogenetics*. 2002 Apr;12(3):265-8.
4. David SP, Niaura RS, Papandonatos GD, Shadel WG, Britt DM, Day A, Stumpff J. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? *Nicotine Tob Res*. 2003 Nov;5(6):935-42.
5. David SP, Taylor JS, Monroe A, Goldman R, Green AR, Boss JD, Sagatias D. Evaluation of an educational intervention for medical students to promote competency in social and community determinants of health. *Annals of Behavioral Science & Medical Education* 2004;10(2):268-273.
6. Munafo M, Bradburn M, Bowes L, David SP. Are there sex differences in transdermal nicotine replacement therapy efficacy? A meta-analysis. *Nicotine Tob Res*. 2004 Oct;6(5):769-76.
7. David SP, Murthy NV, Rabiner EA, Munafo MR, Johnstone EC, Jacob R, Walton RT, Grasby PM. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. *J Neurosci*. 2005 Mar 9;25(10):2586-90.
8. David SP, Munafo' M, Johansen-Berg, H, Smith

- SM, Rogers RD, Matthews PM, Walton RT. Ventral Striatum/Nucleus Accumbens Activation to Smoking-Related Pictorial Cues in Smokers and Non-Smokers: An fMRI study. *Biol Psychiatry*. 2005 Sep 15;58(6):488-94.
9. David S, Evins AE, Lancaster T, Stead LF. Opioid antagonists for smoking cessation. *Cochrane Database Syst Rev*. 2006 Oct 18;(4):CD003086.
  10. David SP, Munafò MR, Murphy MFG, Walton RT, Johnstone EJ. The serotonin transporter (5-HTTLPR) polymorphism and treatment response to nicotine patch in primary care: Follow-up of a randomized controlled trial. *Nicotine Tob Res*. 2007 Feb;9(2):225-31.
  11. David SP, Munafò MR, Murphy MFG, Proctor M, Walton RT, Johnstone EC. Genetic variation in the dopamine D4 Receptor (*DRD4*) gene and smoking cessation: Follow up of a randomised clinical trial of transdermal nicotine patch. *Pharmacogenomics J*. 2007 Mar 27; [Epub ahead of print]
  12. David SP, Brown RA, Papandonatos GD, Lloyd-Richardson EE, Munafò MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. *Nicotine Tob Res*. 2007 (manuscript in press).
  13. Johnstone EC, Elliot KM, David SP, Murphy MFG, Walton RT, Munafò MR. Association of Association of COMT Val108/158Met Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial. *Cancer Epidemiol Biomarkers Prev*. 2007 Jun;16(6):1065-9.
  14. David SP, Strong D, Brown RA, Lloyd-Richardson EE, Wileyto P, Evins AE, Shields PG, Lerman C, Niaura R. Bupropion efficacy for smoking cessation is influenced by the *DRD2*-Taq1A polymorphism: Analysis of pooled data from two clinical trials. *Nicotine Tob Res*. 2007;9(12):1251-1257.
  15. Welton NJ, Johnstone EC, David SP, Munafò

- MR. A Cost-Effectiveness Analysis of Genetic Testing to Aid Treatment Choice for Smoking Cessation. *Nicotine Tob Res.* (manuscript in press).
16. Paul R, Grieve S, Niaura R, David SP, Laidlaw D, Cohen R, Sweet L, Taylor G, Clark R, Pogun S, Gordon E. Impact of cigarette smoking on the microstructural integrity of white matter in healthy adults: a diffusion tensor imaging study. *Nicotine Tob Res.* (manuscript in press).
  17. David SP, Munafo' M, Johansen-Berg, H, MacKillop J, Sweet L, Cohen RA, Rogers RD, Matthews PM, Walton RT. Effects of acute nicotine abstinence on cue-elicited ventral striatum/nucleus accumbens activation in female cigarette smokers: A functional magnetic resonance imaging study. *Brain Imaging & Behavior.* (epup ahead of print).

*Other Manuscripts in Peer-Reviewed Journals:*

18. David SP. The Transatlantic Conference on Tobacco (TACT): A Model for International Tobacco Policy Activism. *J Cancer Ed.* 1998; 13:253-254.
19. David SP, Greer DS. Social marketing: application to medical education. *Ann Intern Med.* 2001 Jan 16;134(2):125-7.
20. David SP. A civic role for physicians in the promotion of global tobacco control. *Fam Pract.* 2001 Feb;18(1):107.
21. David SP. Should we recommend nicotine replacement therapy? *Am Fam Physician.* 2001 Jun 1;63(11):2245-7.
22. David SP. Smoking cessation for the primary care physician. *Primary Care Reports.* 2001;7(24):211-221.
23. David SP. Reflections From a Rotation in Cambridge, England, *Fam Med* 2000;32(5):310-2.
24. David SP. Media advocacy for the office-based teacher of family medicine. *Fam Med* .2001;33(1):13-15.

25. David SP. Should we use antibiotics for acute bacterial conjunctivitis? *Am Fam Physician*. 2002 November 1;66(8):1649-52.
26. David SP. Treatment of viral conjunctivitis in children. *Am Fam Physician* 2003 May 1;67(9):1873.
27. David SP. Should we use multiple risk factor interventions for the primary prevention of coronary heart disease? *Am Fam Physician*. 2002 July 15;66(2):245-6.
28. Stamp M, David SP. Are family practitioners willing to use pharmacogenetics for smoking cessation in their practices? *Fam Med*. 2003 Feb;35(2):83.
29. Gramling R, David SP. Genetic Susceptibility to Cancer: Teaching Points. *Fam Med*. 2003 Jul-Aug;35(7):466-8.
30. David SP, Eaton CB. Comment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels". *Nicotine Tob Res*. 2003 Aug;5(3):397-9.
31. David SP. Should we routine breast cancer screening with mammography for breast cancer screening? *Am Fam Physician*. 2003 Jul 15;68(2):260-2.
32. Munafò M, Bradburn M, Bowes L, David SP. Investigating subgroups in smoking cessation treatment response: Response to Perkins. *Nicotine Tob Res*. 2004 Oct;6(5): 865-867.
33. David SP, Eaton, CB, Taylor, JS, Stamp, MJ, Cyr, M, Siegel, B, Gramling, R, Walton, RT. Envisaging and applying a unifying three-dimensional theoretical framework for generalist physicians. *Med Health R I*. 2004 Nov;87(11):336-40.
34. David SP, Gramling R. Teaching Genetics in Primary Care through a Transatlantic Videoconference. *Nat Rev Genetics*. 25 November 2003 (published online only).
35. Gramling R, David SP, Duffy C. Does providing hereditary breast cancer risk assessment support to practicing physicians decrease the likelihood of them discussing such risk with

their patients? *Genet Med*. 2004 Nov-Dec;6(6):542.

36. David SP. Pharmacogenetics. *Prim Care*. 2004 Sep;31(3):543-559.
37. David SP, Eaton CP, Culpepper L, Goldman E, Borkan J. Building a Successful Research Enterprise in Family Medicine: The Brown Experience. *Med Health R I*. 2006 Aug;89(8):281-4.
38. Long R, David SP, Monroe A, Shaw J. Fellowship training in family medicine at Brown: adding depth to breadth. *Med Health RI*. 2006 Aug;89(8):274-5.
39. Koplan KE, David SP, Rigotti NA. 10-minute consultation: Smoking cessation. *BMJ*. 2007 (manuscript in press).
40. David SP, Smith M, Lee CS. Results from a community-based, participatory smoking cessation program for Latino smokers using nicotine replacement therapy. *Am J Public Health*. (manuscript in press).

*Book Chapters:*

41. David SP, Munafò M, Walton RT. Chapter 21. "The Pharmacogenomics of Nicotine Addiction and smoking cessation" in: Clinical Pharmacogenomics (with emerging Pharmacoproteomics). Eds. Wong S, Linder M, Valdes R, 2006, AACCC Press, Milwaukee, WI.

*Doctoral Thesis:*

42. David SP. *Studies of Genetic Influences on Nicotine Dependence Utilising Functional Neuroimaging*. Submitted August 2005, successfully defended November 2005, revised and bound in the Bodleian Library, University of Oxford in May 2006.